RecruitingNot ApplicableNCT06784440

Search for Noninvasive Markers of "Graft Injury" in Pediatric and Adult Patients With Congenital Heart Disease Undergoing Cardiac Transplantation


Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Enrollment

20 participants

Start Date

Mar 8, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This clinical tissue-based, drug-free, single-center, longitudinal study aims to validate a new diagnostic method, namely, to evaluate whether plasma levels of circulating donor free DNA in the recipient's blood (Dd-cfDNA: donor-derived cell free DNA), in patients undergoing orthotopic heart transplantation, can be predictive of the presence of acute myocardial rejection with the same sensitivity as immunohistochemical analysis on endomyocardial biopsy specimen, the current gold standard for the diagnosis of acute cell-mediated myocardial rejection, in a population consisting of pediatric patients and adult patients with congenital heart disease undergoing orthotopic heart transplantation.


Eligibility

Max Age: 44 Years

Inclusion Criteria3

  • Adult patients with congenital heart disease undergoing cardiac transplantation at our center or other centers, followed in follow-up at our center (Unit of Pediatric Cardiology and Developmental Age, IRCCS Azienda Ospedaliero-Universitaria di Bologna)
  • Pediatric patients undergoing cardiac transplantation at our center or other centers but followed in follow-up at our center
  • Obtaining informed consent from the adult patient or parent/guardian in case of minor

Exclusion Criteria1

  • Failure to obtain informed consent from the adult patient or parent/guardian in case of minor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

GENETICEvaluation of circulating donor free DNA in the recipient's blood (Dd-cfDNA: donor-derived cell free DNA)

From the blood samples taken, 2 mL of plasma separated from blood will be stored in EDTA frozen at -80°C. This material will later be processed by NGS run using of CareDX kits. The result will be provided by dedicated software as percentage of donor DNA in relation to recipient DNA.


Locations(1)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Bologna, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06784440


Related Trials